Donald Trump's announcement that Elon Musk and Vivek Ramaswamy will lead a newly formed Department of Government Efficiency ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

One of Chicago's richest dynasties built one of the world’s biggest health-care fortunes over the past century, but these ...

Ray Dalio’s firm cuts 20% of its Microsoft stock holding, signaling a shift in tech focus. Cathie Wood’s Ark Invest also ...

Successfully navigating a drug development cycle is a major undertaking. On average, the sequence takes over a decade to ...

Bank of America sees strong M&A potential in banking and biotech, with financials historically more active under Republicans.

Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...